Adil Wani, MD
Cardiovascular Disease · Elkhart, INNPI 1114335866
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.5%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Abbott at 26.0% of the total.
Across 399 payments — averaging $61.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Medtronic$5K
- Boston Scientific$4K
- Edwards Lifesciences$3K
- Abiomed$937
- Novartis$731
- plus $4K from 33 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Grants$1,6417%
- Travel & lodging$8,49134%
- Food & beverage$13,46654%
- Education$1,1145%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$3,731
- MitraClip$2,060
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,419
- AMPLATZER AMULET$1,319
- GENERAL - STRUCTURAL HEART$1,105
- SUPERA$974
- GENERAL ATHERECTOMY$653
- SAPIEN 3 Ultra RESILIA$591
- GENERAL VASCULAR ACCESS$534
- WATCHMAN Access System$372
- WATCHMAN FLX$367
- Endurant$284
- AVVIGO Guidance System$257
- Impella$256
- MitraClip System$231
- XARELTO$223
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$210
- HeartMate 3 Left Ventricular Assist Device$163
- Dragonfly OCT$162
- Barostim Neo System$138
How this compares
$24,711 in reported general payments places this provider in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 201 | $224,193 |
| EntrestoSacubitril/Valsartan | 133 | $181,095 |
| JardianceEmpagliflozin | 106 | $125,092 |
| FarxigaDapagliflozin Propanediol | 96 | $101,931 |
| XareltoRivaroxaban | 51 | $59,848 |
| MultaqDronedarone Hcl | 16 | $32,023 |
| Repatha SureclickEvolocumab | 28 | $24,212 |
| BrilintaTicagrelor | 36 | $21,587 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $8,199 |
| Praluent PenAlirocumab | 11 | $7,685 |
| Metoprolol Succinate | 335 | $3,682 |
| Ranolazine ErRanolazine | 45 | $3,332 |
| Atorvastatin Calcium | 427 | $3,146 |
| Prasugrel Hcl | 35 | $2,508 |
| Amiodarone Hcl | 49 | $2,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $183 | $224,193201 claims |
| NovartisEntresto | $731 | $181,095133 claims |
| Boehringer IngelheimJardiance | $102 | $125,092106 claims |
| AstraZenecaFarxiga, Brilinta | $41 | $123,517132 claims |
| Johnson & JohnsonXarelto | $399 | $59,84851 claims |
| Sanofi-aventis U.S. LLCMultaq | $29 | $32,02316 claims |
| Esperion Therapeutics, Inc.Nexlizet | $74 | $8,19916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Elkhart
- Wai LeeElkhart$321K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.